SEMAX 5 mg Deus Medical is a peptide product containing Semax, a synthetic heptapeptide derived from the ACTH(4–7) sequence with a C-terminal Pro-Gly-Pro extension. Deus Medical currently lists SEMAX as a 5 mg per vial presentation and provides CAS number 80714-61-0, molecular weight 813.93 g/mol, and formula C37H51N9O10S.

SEMAX 5 mg Deus Medical Product Overview

Semax has been studied as a synthetic neuropeptide in biochemical, preclinical, and clinical research. Published literature has investigated its biological activity and nervous-system signaling. However, research findings should remain separate from claims about a specific commercial product. The availability of a 5 mg vial does not independently establish safety, efficacy, or regulatory approval.

Deus Medical identifies its presentation as SEMAX Heptapeptide and states that each vial contains 5 mg of Semax with excipients. The manufacturer’s product page also provides an authenticity QR-code feature. Use these details to compare the label with manufacturer information.

SEMAX 5 mg Deus Medical Specifications

Product name: SEMAX
Brand: Deus Medical
Active compound: Semax heptapeptide
Stated strength: 5 mg per vial
CAS number: 80714-61-0
Molecular weight: 813.93 g/mol
Molecular formula: C37H51N9O10S
Product category: Peptide
Presentation: Verify current vial and packaging
Composition: Semax 5 mg plus excipients, according to Deus Medical

Check the strength, batch number, expiration information, packaging, and manufacturer details. If a certificate of analysis is supplied, compare its identifiers with the package.

Semax Research and Regulatory Context

Scientific publications have examined Semax in different experimental settings. For example, PubMed records research involving Semax and enkephalin-degrading enzymes, while more recent preclinical work has investigated Semax in animal models. Other published studies have evaluated the peptide in clinical settings. These studies provide research context but do not establish identical quality across commercial presentations or a particular medical use.

Regulatory status also requires careful wording. FDA states that Semax is not an ingredient in an FDA-approved drug and that there is no applicable USP or NF drug-substance monograph for Semax free base or Semax acetate. FDA has also evaluated Semax as a bulk substance for compounding. Therefore, a commercial 5 mg presentation should not be represented as FDA-approved.

Product Verification and Ordering Information

Iron Elite Nutrition can provide product-listing information for SEMAX 5 mg Deus Medical, including its stated strength and manufacturer reference. Before purchasing, review the product details and compare them with the physical packaging. Confirm the lot number, expiration date, authenticity information, and laboratory documentation.

A transparent product page should distinguish manufacturer information from independent evidence and avoid unsupported claims concerning cognition, mood, neurological recovery, immunity, or other outcomes. Dosing schedules and self-treatment recommendations should not be inferred from the listing.

SEMAX 5 mg Quality Checks

When evaluating SEMAX 5 mg Deus Medical, confirm the product name, 5 mg quantity, CAS number, manufacturer identification, batch information, and packaging condition. If analytical documentation is available, verify that its identifiers correspond to the specific product batch. These checks help establish product identity without overstating the evidence.

Semax is a specialized research peptide, but regulatory status differs by jurisdiction. In the United States, FDA documentation does not recognize Semax as an ingredient of an FDA-approved drug. Product descriptions should therefore focus on identification, specifications, research context, and verification rather than presenting Semax as an approved treatment.

For current product information, visit Iron Elite Nutrition and review the SEMAX 5 mg listing carefully today. Verify the manufacturer, formulation, packaging, batch documentation, and applicable regulatory requirements before relying on a commercial peptide product.